Balentine LLC boosted its stake in shares of Celgene Co. (NASDAQ:CELG) by 83.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,057 shares of the biopharmaceutical company’s stock after acquiring an additional 481 shares during the quarter. Balentine LLC’s holdings in Celgene were worth $137,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in CELG. Thompson Davis & CO. Inc. increased its position in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares in the last quarter. Motco increased its position in shares of Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Celgene in the second quarter valued at approximately $129,000. Acropolis Investment Management LLC purchased a new stake in shares of Celgene in the second quarter valued at approximately $144,000. Finally, Rational Advisors LLC purchased a new stake in shares of Celgene in the second quarter valued at approximately $156,000. Institutional investors own 80.17% of the company’s stock.
In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders own 0.95% of the company’s stock.
Celgene Co. (CELG) opened at $106.09 on Monday. The firm has a market capitalization of $83,530.00, a price-to-earnings ratio of 16.58, a price-to-earnings-growth ratio of 0.82 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 earnings per share. equities analysts forecast that Celgene Co. will post 6.67 EPS for the current fiscal year.
A number of analysts have recently commented on the company. Atlantic Securities upgraded Celgene from a “neutral” rating to an “overweight” rating in a research report on Friday. Cann restated a “buy” rating and issued a $166.00 price objective on shares of Celgene in a research report on Wednesday, November 22nd. TheStreet cut Celgene from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. BMO Capital Markets boosted their price objective on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, November 17th. Finally, Canaccord Genuity set a $140.00 price target on Celgene and gave the stock a “buy” rating in a research note on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $139.57.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.